Business Context and Reporting Period
This Form 8-K is a current report filed by Theravance Biopharma, Inc. on August 25, 2026. The filing primarily addresses Item 8.01 (Other Events) regarding the release of a presentation on the Phase 3 CYPRESS Study (0197) for ampreloxetine in patients with neurogenic orthostatic hypotension (nOH) associated with multiple system atrophy (MSA). The report also references a proposed transaction with Zymeworks Inc. announced on June 29, 2026.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a current report focused on clinical updates and corporate events rather than a periodic financial statement.
Material Changes and Events
- Clinical Update: The Company made available a presentation detailing post hoc analyses of the CYPRESS Study (0197) and interactions with the U.S. Food and Drug Administration (FDA) regarding the ampreloxetine development program.
- Corporate Transaction: The filing references a proposed transaction between Theravance Biopharma and Zymeworks Inc. (Parent), for which a Definitive Proxy Statement was filed on August 21, 2026.
Guidance, Outlook, and Risks
The filing contains extensive forward-looking statements and risk disclosures related to both the clinical program and the proposed merger.
- Clinical Risks: Post hoc and exploratory analyses may not be replicated; the FDA may reject study designs or require additional trials; pivotal trials may be delayed or unsuccessful; and no marketing application may be approved.
- Transaction Risks: Risks include the potential failure to obtain shareholder approval for the Zymeworks transaction, delays in the transaction, uncertainty regarding contingent value rights, potential litigation, competing offers, and employee retention issues.
- Regulatory Status: The information in the presentation is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review the Definitive Proxy Statement (Schedule 14A) filed on August 21, 2026, for details on the proposed transaction with Zymeworks Inc.
- Examine Exhibit 99.1 attached to this filing for the full slide presentation on the CYPRESS Study (0197) and ampreloxetine data.
- Verify the status of the shareholder vote required to approve the proposed transaction.
- Monitor FDA communications regarding the ampreloxetine clinical development program and potential requirements for additional trials.